Mavacamten Shows Promise in Heart Failure With Normal to Supranormal EF
Meeting Coverage > > HFSA-- Cardiac myosin inhibitor connected to enhancements in biomarkers in little research study
by Nicole Lou, Senior Staff Writer, MedPage Today September 30, 2024
There might be a future for heart myosin inhibitors in cardiac arrest with maintained ejection portion (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial.
A recognized heart myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) revealed prospective for decreasing myocardial wall tension and cardiomyocyte injury in 30 HFpEF clients with a left ventricular ejection portion (LVEF) in the upper variety of regular or greater (60% a...